JAGSNPHARM.NS WACC - Weighted Average Cost of Capital

The WACC of Jagson Pal Pharmaceuticals Ltd (JAGSNPHARM.NS) is 14.1%.

The Cost of Equity of Jagson Pal Pharmaceuticals Ltd (JAGSNPHARM.NS) is 14.20%.

The Cost of Debt of Jagson Pal Pharmaceuticals Ltd (JAGSNPHARM.NS) is 7.50%.

	Range	Selected
Cost of equity	13.00% - 15.40%	14.20%
Tax rate	22.70% - 23.90%	23.30%
Cost of debt	7.50% - 7.50%	7.50%
WACC	12.9% - 15.4%	14.1%

WACC

JAGSNPHARM.NS WACC calculation

Category	Low	High

Long-term bond rate	6.9%	7.4%
Equity market risk premium	8.3%	9.3%
Adjusted beta	0.73	0.81

Additional risk adjustments	0.0%	0.5%
Cost of equity	13.00%	15.40%

Tax rate	22.70%	23.90%
Debt/Equity ratio	0.01	0.01
Cost of debt	7.50%	7.50%

After-tax WACC	12.9%	15.4%


Selected WACC	14.1%

JAGSNPHARM.NS's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for JAGSNPHARM.NS:

cost_of_equity (14.20%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (0.73) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.